These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 26951894

  • 1. 1,2,4-Triazolyl octahydropyrrolo[2,3-b]pyrroles: A new series of potent and selective dopamine D3 receptor antagonists.
    Micheli F, Bernardelli A, Bianchi F, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Oliosi B, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1619-36. PubMed ID: 26951894
    [Abstract] [Full Text] [Related]

  • 2. 1,2,4-Triazolyl 5-Azaspiro[2.4]heptanes: Lead Identification and Early Lead Optimization of a New Series of Potent and Selective Dopamine D3 Receptor Antagonists.
    Micheli F, Bacchi A, Braggio S, Castelletti L, Cavallini P, Cavanni P, Cremonesi S, Dal Cin M, Feriani A, Gehanne S, Kajbaf M, Marchió L, Nola S, Oliosi B, Pellacani A, Perdonà E, Sava A, Semeraro T, Tarsi L, Tomelleri S, Wong A, Visentini F, Zonzini L, Heidbreder C.
    J Med Chem; 2016 Sep 22; 59(18):8549-76. PubMed ID: 27564135
    [Abstract] [Full Text] [Related]

  • 3. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
    Micheli F, Arista L, Bertani B, Braggio S, Capelli AM, Cremonesi S, Di-Fabio R, Gelardi G, Gentile G, Marchioro C, Pasquarello A, Provera S, Tedesco G, Tarsi L, Terreni S, Worby A, Heidbreder C.
    J Med Chem; 2010 Oct 14; 53(19):7129-39. PubMed ID: 20839775
    [Abstract] [Full Text] [Related]

  • 4. Triazolyl azabicyclo[3.1.0]hexanes: A class of potent and selective dopamine D(3) receptor antagonists.
    Bonanomi G, Braggio S, Capelli AM, Checchia A, Di Fabio R, Marchioro C, Tarsi L, Tedesco G, Terreni S, Worby A, Heibreder C, Micheli F.
    ChemMedChem; 2010 May 03; 5(5):705-15. PubMed ID: 20232439
    [Abstract] [Full Text] [Related]

  • 5. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis.
    Whiting RL, Choppin A, Luehr G, Jasper JR.
    J Pharmacol Exp Ther; 2021 Oct 03; 379(1):85-95. PubMed ID: 34253646
    [Abstract] [Full Text] [Related]

  • 6. Novel, Selective, and Developable Dopamine D3 Antagonists with a Modified "Amino" Region.
    Micheli F.
    ChemMedChem; 2017 Aug 22; 12(16):1254-1260. PubMed ID: 28426179
    [Abstract] [Full Text] [Related]

  • 7. 1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.
    Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Fabio RD, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, Macdonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby CR, Hagan JJ, Heidbreder C.
    J Med Chem; 2007 Oct 18; 50(21):5076-89. PubMed ID: 17867665
    [Abstract] [Full Text] [Related]

  • 8. 1,2,4-Triazolyl azabicyclo[3.1.0]hexanes: a new series of potent and selective dopamine D(3) receptor antagonists.
    Micheli F, Arista L, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Damiani F, Di-Fabio R, Fontana S, Gentile G, Griffante C, Hamprecht D, Marchioro C, Mugnaini M, Piner J, Ratti E, Tedesco G, Tarsi L, Terreni S, Worby A, Ashby CR, Heidbreder C.
    J Med Chem; 2010 Jan 14; 53(1):374-91. PubMed ID: 19891474
    [Abstract] [Full Text] [Related]

  • 9. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH.
    J Med Chem; 2005 Feb 10; 48(3):839-48. PubMed ID: 15689168
    [Abstract] [Full Text] [Related]

  • 10. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA, Roof RA, Moritz AE, Miller BN, Doyle TB, Free RB, Banala AK, Paul NM, Kumar V, Sibley CD, Newman AH, Sibley DR.
    Eur Neuropsychopharmacol; 2015 Sep 10; 25(9):1448-61. PubMed ID: 25583363
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and binding affinity of new 1,4-disubstituted triazoles as potential dopamine D(3) receptor ligands.
    Insua I, Alvarado M, Masaguer CF, Iglesias A, Brea J, Loza MI, Carro L.
    Bioorg Med Chem Lett; 2013 Oct 15; 23(20):5586-91. PubMed ID: 24012118
    [Abstract] [Full Text] [Related]

  • 12. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
    Campiani G, Nacci V, Bechelli S, Ciani SM, Garofalo A, Fiorini I, Wikström H, de Boer P, Liao Y, Tepper PG, Cagnotto A, Mennini T.
    J Med Chem; 1998 Sep 24; 41(20):3763-72. PubMed ID: 9748351
    [Abstract] [Full Text] [Related]

  • 13. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 14. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
    Butini S, Brindisi M, Gemma S, Minetti P, Cabri W, Gallo G, Vincenti S, Talamonti E, Borsini F, Caprioli A, Stasi MA, Di Serio S, Ros S, Borrelli G, Maramai S, Fezza F, Campiani G, Maccarrone M.
    J Med Chem; 2012 Aug 09; 55(15):6898-915. PubMed ID: 22779702
    [Abstract] [Full Text] [Related]

  • 15. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.
    Seeman P, Guan HC.
    Synapse; 2009 Aug 09; 63(8):705-9. PubMed ID: 19391149
    [Abstract] [Full Text] [Related]

  • 16. Novel morpholine scaffolds as selective dopamine (DA) D3 receptor antagonists.
    Micheli F, Cremonesi S, Semeraro T, Tarsi L, Tomelleri S, Cavanni P, Oliosi B, Perdonà E, Sava A, Zonzini L, Feriani A, Braggio S, Heidbreder C.
    Bioorg Med Chem Lett; 2016 Feb 15; 26(4):1329-32. PubMed ID: 26786693
    [Abstract] [Full Text] [Related]

  • 17. Dopamine D3 receptor antagonists: the quest for a potentially selective PET ligand. Part one: lead identification.
    Holmes IP, Micheli F, Gaines S, Lorthioir O, Watson SP, Fabio RD, Gentile G, Heidbreder C, Savoia C, Worby A.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4799-801. PubMed ID: 19560918
    [Abstract] [Full Text] [Related]

  • 18. Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
    Zhao C, Sun M, Bennani YL, Miller TR, Witte DG, Esbenshade TA, Wetter J, Marsh KC, Hancock AA, Brioni JD, Cowart MD.
    J Med Chem; 2009 Aug 13; 52(15):4640-9. PubMed ID: 19588934
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands.
    Zhou B, Ji M, Cai J.
    Bioorg Chem; 2018 Apr 13; 77():125-135. PubMed ID: 29353729
    [Abstract] [Full Text] [Related]

  • 20. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
    Wood M, Ates A, Andre VM, Michel A, Barnaby R, Gillard M.
    Mol Pharmacol; 2016 Feb 13; 89(2):303-12. PubMed ID: 26655303
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.